Do you assess the cardiovascular risk of patients before starting antigen deprivation therapy for prostate cancer?

0 votes
Yes, in all patients, and I actively monitor their cardiovascular health during treatment
 
0% / 0 votes
Yes, at baseline, but I do not monitor their cardiovascular health during treatment except if signs or symptoms develop
 
0% / 0 votes
Only in patients with additional risk factors, but not in all patients
 
0% / 0 votes
Not usually, but I monitor their cardiovascular health during treatment
 
0% / 0 votes
Not as a routine procedure
 
0% / 0 votes


Click here to share poll on specific pages, user profiles or purchase votes!